Does dexrazoxane prevent cardiotoxicity and tissue injuries in patients receiving anthracycline-based chemotherapy?
This review summarizes the historical, preclinical, and clinical background of dexrazoxane for preventing anthracycline-induced cardiotoxicity and extravasation injuries.
For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
Seppo W. Langer (Mon,) studied this question.